Posted by Michael Wonder on 31 Oct 2022
Expanded access to COVID-19 oral antiviral treatments on the PBS
1 November 2022 - Expanded eligibility criteria for COVID-19 oral anti-viral treatments (Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and ritonavir)
Eligibility for PBS access to COVID-19 oral antiviral treatments, Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and ritonavir) will be widened from 1 November 2022.
